Compare Neurocrine Biosciences Inc (NBIX) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco NASDAQ 100 ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while Invesco NASDAQ 100 ETF trades at $297.55. The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | QQQM | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $307.23 |
52-Week Low | $123.10 | $229.87 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
QQQM trades at $297.98, up 0.4% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with lower fees than its QQQ counterpart, making it attractive for long-term investors. Recent news highlights its popularity among growth-focused investors and retirees seeking exposure to technology and innovation stocks.
The ETF's performance remains tied to the 'Magnificent Seven' tech stocks, with historical annual returns around 14%. While technical indicators show bullish momentum, the elevated RSI suggests potential near-term consolidation. Key risks include concentration in tech sector and market volatility affecting growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
